{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-068263","form_type":"8-K","ticker":"SMNR","cik":"0001913577","company_name":"Semnur Pharmaceuticals, Inc.","filed_at":"2025-07-28T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.577043+00:00","generated_at":"2026-05-18T00:27:47.708923+00:00","sec_items":["1.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Denali Capital Acquisition Corp. enters Amendment No. 2 to Merger Agreement with Semnur Pharmaceuticals","bullets":["Amendment No. 2 signed on July 22, 2025 modifies Exchange Ratio and Merger Consideration definitions.","Allows issuance of additional Semnur common shares pre-closing for private placement financing or advisor services.","Maintains the 1.25-to-1 exchange ratio between Denali and Semnur shares.","Parties include Denali Capital Acquisition Corp., Denali Merger Sub Inc., and Semnur Pharmaceuticals (Scilex subsidiary)."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-068263","json":"https://secwatch.observer/filing/0001213900-25-068263.json","markdown":"https://secwatch.observer/filing/0001213900-25-068263.md","text":"https://secwatch.observer/filing/0001213900-25-068263.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1913577/000121390025068263/0001213900-25-068263-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1913577/000121390025068263/ea025050601-8k425_denali.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-18T00:27:47.708923+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}